ArticlePloS one2016
Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Irritability as an independent predictor of concurrent and future suicidal ideation in adults with stimulant use disorder: Findings from the STRIDE study.Journal of affective disorders · 2021Trial
- Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project.The Journal of clinical psychiatry · 2021Trial
- Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.The international journal of neuropsychopharmacology · 2019Trial
- Factors linked to depressive symptoms in obsessive-compulsive disorder: a machine learning and network analysis from China OCD Cohort (COCC).BMC psychiatry · 2026Article
- Longitudinal bidirectional association between psychosocial function and depression in Chinese patients with clinically remitted depression: a cross-lagged panel model analysis.BMC psychiatry · 2025Article
- Article
- Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics.Advances in neurobiology · 2023Article
- Development of a psychosocial functioning questionnaire for patients with major depressive disorder.General psychiatry · 2022Article
- Remission of symptoms is not equal to functional recovery: Psychosocial functioning impairment in major depression.Frontiers in psychiatry · 2022Review
- Validation of the German version of the work and social adjustment scale in a sample of depressed patients.BMC health services research · 2021Article
- Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date.Drug design, development and therapy · 2021Review
- Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study.Psychiatric research and clinical practice · 2020Article
- Redefining Therapeutic Outcomes of Depression Treatment.Journal for person-oriented research · 2019Article
- Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"Focus (American Psychiatric Publishing) · 2018Article
- Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.International journal of molecular sciences · 2018Review
- Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder.Neuropsychiatric disease and treatment · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The goal of this study was to evaluate the relationship between early change in psychosocial function independent of depression severity and longer-term symptomatic remission. Participants of Combining Medications to Enhance Depression Outcomes trial were randomly selected for model selection (n = 334) and validation (n = 331). Changes in psychosocial function (Work and Social Adjustment Scale, WSAS) from baseline to week 6 were assessed and two data-driven sub-groups of WSAS change were identified in the randomly selected model selection half. Results of analyses to predict symptomatic remission at 3 and 7 months were validated for these sub-groups in the second half (validation sample). From baseline to week 6, psychosocial function improved significantly even after adjusting for depression severity at each visit and select baseline variables (age, gender, race, ethnicity, education, income, employment, depression onset before age 18, anxious features, and suicidal ideation), treatment-arm, and WSAS score. The WSAS change patterns identified two (early improvement and gradual change) subgroups. After adjusting for baseline variables and remission status at week 6, participants with early improvement in the second half (validation sample) had greater remission rates than those with gradual change at both 3 (3.3 times) and 7 months (2.3 times) following acute treatment initiation. In conclusion, early improvement in psychosocial function provides a clinically meaningful prediction of longer-term symptomatic remission, independent of depression symptom severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.